Advantage Trust Co Acquires Shares of 200 Stryker Co. (NYSE:SYK)

Advantage Trust Co bought a new position in shares of Stryker Co. (NYSE:SYK) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 200 shares of the medical technology company’s stock, valued at approximately $60,000.

A number of other institutional investors also recently modified their holdings of SYK. Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the period. Rogco LP bought a new stake in shares of Stryker during the 4th quarter worth $30,000. HBC Financial Services PLLC acquired a new stake in Stryker in the fourth quarter valued at about $37,000. Bourgeon Capital Management LLC bought a new position in Stryker in the fourth quarter valued at about $37,000. Finally, Operose Advisors LLC raised its stake in Stryker by 308.6% during the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after acquiring an additional 108 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is currently owned by corporate insiders.

Stryker Stock Up 0.5 %

SYK stock traded up $1.58 during mid-day trading on Thursday, reaching $330.86. 980,396 shares of the company traded hands, compared to its average volume of 1,327,501. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The firm’s 50 day moving average price is $345.60 and its 200 day moving average price is $318.91. The stock has a market cap of $126.04 billion, a price-to-earnings ratio of 37.77, a P/E/G ratio of 2.54 and a beta of 0.91. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm had revenue of $5.24 billion during the quarter, compared to analyst estimates of $5.10 billion. During the same quarter in the prior year, the business posted $2.14 EPS. The business’s revenue was up 9.7% compared to the same quarter last year. As a group, equities research analysts predict that Stryker Co. will post 11.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Barclays increased their price objective on shares of Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. BTIG Research raised their price objective on Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Roth Mkm upped their target price on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Royal Bank of Canada lifted their price target on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Finally, Wells Fargo & Company upped their price objective on Stryker from $364.00 to $381.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $365.94.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.